As part of a long-term partnership between Spain’s Laboratorios Farmacéuticos Rovi and Moderna, the former company is bringing a new plant into the mix for...

After a busy 2023 marked by multiple drug approvals, UCB isn’t resting on its laurels. This year, the company is focused on growing its blockbuster hopeful Bimzel...

Two months ago, when a federal appeals court rejected United Therapeutics’ attempt to revive an invalidated patent on its aging pulmonary arterial hypertension drug ...

As Sanofi continues to plot its planned separation from its consumer healthcare division, the business has reportedly attracted interest from multiple private equity...

The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for...

On AbbVie’s latest earnings call, analysts were curious whether long-time CEO Richard Gonzalez was weighing a succession plan now that Humira’s loss of U.S. exclusiv...

While the biopharma industry flocks to antibody-drug conjugates because of their ability to act as guided biological missiles to eliminate cancer cells, some co...

Over the last month, for those watching HBO’s macabre “True Detective: Night Country”—a TV series set in a harsh, sunless winter in a fictional Alaskan town—a contin...

Biogen’s business has been in decline thanks to fierce multiple sclerosis competition and a botched Alzheimer’s drug launch. To make matters worse, the U.S. Dep...

After trimming its headcount last year in an effort to cut down on operational expenses, VBI Vaccines found another way to improve its financial position with a...